Congress Asset Management Co. Sells 14,601 Shares of IDEXX Laboratories, Inc. $IDXX

Congress Asset Management Co. decreased its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,592 shares of the company’s stock after selling 14,601 shares during the quarter. Congress Asset Management Co. owned approximately 0.22% of IDEXX Laboratories worth $91,692,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Horizons Wealth Management bought a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $52,000. CX Institutional acquired a new stake in IDEXX Laboratories during the third quarter worth approximately $338,000. QRG Capital Management Inc. lifted its position in IDEXX Laboratories by 16.8% during the second quarter. QRG Capital Management Inc. now owns 3,323 shares of the company’s stock worth $1,749,000 after acquiring an additional 477 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its holdings in shares of IDEXX Laboratories by 2.7% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 28,991 shares of the company’s stock worth $15,262,000 after acquiring an additional 761 shares during the period. Finally, National Pension Service grew its position in shares of IDEXX Laboratories by 5.6% in the second quarter. National Pension Service now owns 129,305 shares of the company’s stock valued at $68,071,000 after purchasing an additional 6,885 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of the company’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares of the company’s stock, valued at approximately $5,090,941.44. This represents a 18.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.79% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on IDXX shares. UBS Group upped their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Barclays dropped their price objective on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. Finally, Citigroup boosted their price objective on shares of IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX traded down $11.66 during mid-day trading on Tuesday, reaching $515.41. The company had a trading volume of 502,349 shares, compared to its average volume of 568,822. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a one year low of $500.61 and a one year high of $769.98. The firm has a market cap of $40.60 billion, a price-to-earnings ratio of 36.25, a PEG ratio of 2.77 and a beta of 1.55. The business’s 50-day simple moving average is $541.95 and its 200 day simple moving average is $554.28.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping the consensus estimate of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analysts’ expectations of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts predict that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) develops and provides diagnostic, information technology and water-testing products and services. The company primarily serves the companion animal veterinary market, helping veterinary practices diagnose and manage diseases through laboratory testing, in-house analyzers, diagnostic kits, imaging systems, software and related consumables.

IDEXX’s companion animal offerings include its IDEXX Reference Laboratories, IDEXX VetLab instruments and software, SNAP rapid tests, and practice-management and data solutions.